Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Anna Moneymaker/Getty Images

The Biden administration will buy 500 million doses of the Pfizer-BioNTech coronavirus vaccine to share with countries around the world, with the option to buy an additional 200 million, two sources familiar with the deal tell Axios.

Why it matters: That's a big step toward making the U.S. a major global vaccine supplier and comes as Biden departs for his first foreign trip as president.

Details: The doses were purchased at a not-for-profit price rather than the $19.50 per dose the U.S. paid in its initial Pfizer contract, according to the sources. Most or all of the doses will be distributed through the global COVAX mechanism.

  • The administration has already said that Biden will press other rich democracies to share doses, including at the G7 on June 11–13. Biden laid out a plan to share an initial 25 million doses last week.
  • Driving the news: Around 200 million available this year and another 300 million in the first half of next year, Politico reports. The Washington Post first reported the purchase of 500 million additional doses.
  • What to watch: Biden could potentially pursue similar deals with Moderna and Johnson & Johnson.

The big picture: Biden had employed an "Americans first" approach until very recently, keeping almost all doses produced in the U.S. at home. The U.S. is second in production only to China, which has been sharing and selling doses all over the world.

  • Now with demand slackening at home, the Biden administration has started to shift its focus to donations while also allowing companies like Pfizer and Moderna to start exporting doses.
  • But based on existing contracts, those companies would be expected to ship a large percentage of doses to rich countries. By buying the doses, the U.S. will be in control of where they are sent.
  • It could also give the U.S. flexibility to donate doses now with the confidence that it has a secure future supply of doses in case they are needed for boosters or to vaccinate additional populations, like children.

The state of play: Rich countries like the U.S. still control the lion's share of global doses even as vaccination rates remain below 1% in sub-Saharan Africa and supply is desperately needed in countries like Brazil or Nepal.

  • Meanwhile, the COVAX initiative, which was designed to supply doses to low- and middle-income countries all over the world, is months behind schedule because of export curbs from hard-hit India.
  • That puts additional pressure on the likes of the European Union, another big vaccine producer, to expedite plans to share doses globally.

Go deeper

Team Biden tiptoes around vaccine-for-migration cooperation

Vice President Kamala Harris speaks today during her closing news confernece in Mexico City. Photo: Alfredo Estrella/AE/AFP via Getty Images

Vice President Kamala Harris headed back to the U.S. after two days of high-level meetings in Guatemala and Mexico about corruption, human trafficking and migration, but one subject was only briefly touched upon: coronavirus vaccines.

Why it matters: Migrant apprehensions at the U.S.-Mexico border remain near 20-year highs. Harris is charged with trying to resolve the root causes for people leaving Central America, issues oftentimes exacerbated by COVID-19 in recent months.

CDC: Severe COVID cases, deaths plummeted in spring following vaccine

Data: Our World in Data; Chart: Axios Visuals

COVID-19 cases, deaths, related hospitalizations and ER visits have all declined considerably this year, especially among older, vaccinated adults, according to a new CDC report.

Why it matters: The data bears it out: Greater vaccine coverage in the U.S. is correlated with a precipitous drop in the number of people getting seriously ill.

Jun 9, 2021 - Health

Fauci sounds alarm over COVID-19 variant surging in U.K.

Anthony Fauci urged Americans Wednesday to get vaccinated to halt the spread of the highly transmissible COVID-19 variant first discovered in India, which currently accounts for 6% of infections in the U.S.

Why it matters: The United Kingdom has seen an explosion in new cases as a result of the variant, which is now the dominant strain and may be associated with increased disease severity.